1. Home
  2. XBIT vs ELA Comparison

XBIT vs ELA Comparison

Compare XBIT & ELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.55

Market Cap

75.0M

Sector

Health Care

ML Signal

HOLD

Logo Envela Corporation

ELA

Envela Corporation

HOLD

Current Price

$17.85

Market Cap

449.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
ELA
Founded
2005
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Consumer Specialties
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
75.0M
449.7M
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
XBIT
ELA
Price
$2.55
$17.85
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$16.50
AVG Volume (30 Days)
26.4K
69.1K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
115.38
EPS
N/A
0.56
Revenue
N/A
$241,021,362.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$22.54
P/E Ratio
N/A
$31.71
Revenue Growth
N/A
33.62
52 Week Low
$2.09
$5.33
52 Week High
$3.61
$18.98

Technical Indicators

Market Signals
Indicator
XBIT
ELA
Relative Strength Index (RSI) 67.38 64.78
Support Level $2.15 $16.09
Resistance Level $2.69 $18.29
Average True Range (ATR) 0.07 0.79
MACD 0.02 -0.07
Stochastic Oscillator 84.38 62.68

Price Performance

Historical Comparison
XBIT
ELA

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

Share on Social Networks: